Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.80 -2.0%	$17.69	$13.53 ▼ $35.25	$1.69B	2.09	1.49 million shs	4.49 million shs
GLPG Galapagos	$27.98 -0.3%	$27.57	$22.36 ▼ $31.23	N/A	0.07	250,589 shs	183,086 shs
HRMY Harmony Biosciences	$31.98 +0.4%	$32.92	$26.47 ▼ $41.61	$1.84B	0.87	626,390 shs	1.45 million shs
PRTC PureTech Health	$17.15 -4.4%	$17.77	$13.30 ▼ $25.00	$411.94M	1.15	5,008 shs	40,178 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+0.24%	+6.73%	-13.98%	-28.30%
GLPG Galapagos	0.00%	+2.04%	-3.58%	+11.39%	+12.91%
HRMY Harmony Biosciences	0.00%	+0.28%	-6.98%	-3.65%	+6.00%
PRTC PureTech Health	0.00%	-5.87%	-7.35%	-13.30%	-31.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.3103 of 5 stars	3.5	1.0	2.2	2.5	0.6
GLPG Galapagos	0.3574 of 5 stars	0.8	3.0	1.9	0.0	0.6
HRMY Harmony Biosciences	4.7685 of 5 stars	4.6	1.0	2.8	3.3	4.4
PRTC PureTech Health	2.6065 of 5 stars	3.8	5.0	2.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	190.18% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-9.46% Downside
HRMY Harmony Biosciences	3.13	Buy	$53.63	67.68% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	162.39% Upside

Current Analyst Ratings Breakdown

Latest PRTC, HRMY, BEAM, and GLPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
4/8/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/8/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.60	N/A	N/A	$8.86 per share	1.90
GLPG Galapagos	$298.31M	N/A	$0.73 per share	38.54	$47.57 per share	N/A
HRMY Harmony Biosciences	$714.73M	2.57	$2.95 per share	10.85	$11.56 per share	2.77
PRTC PureTech Health	$4.83M	85.29	$2.39 per share	7.19	$17.04 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	12.21	10.28	0.47	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/30/2025 (Estimated)

Latest PRTC, HRMY, BEAM, and GLPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	GLPG Galapagos	-$0.34	N/A	N/A	N/A	$80.13 million	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
GLPG Galapagos	N/A	7.95	7.86
HRMY Harmony Biosciences	0.22	3.67	3.63
PRTC PureTech Health	N/A	9.33	9.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
GLPG Galapagos	32.46%
HRMY Harmony Biosciences	86.23%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
GLPG Galapagos	2.91%
HRMY Harmony Biosciences	23.60%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
PRTC PureTech Health	100	24.02 million	22.75 million	Not Optionable

PRTC, HRMY, BEAM, and GLPG Headlines

Recent News About These Companies

Why This Biotech Stock Just Doubled In A Single Day

June 26, 2025 | benzinga.com

Millennium Management LLC Invests $823,000 in PureTech Health plc (NASDAQ:PRTC)

June 7, 2025 | marketbeat.com

PureTech Health plc (NASDAQ:PRTC) Sees Large Decline in Short Interest

June 3, 2025 | marketbeat.com

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

May 22, 2025 | businesswire.com

PureTech’s deupirfenidone shows strong and durable efficacy

May 21, 2025 | thepharmaletter.comT

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

May 9, 2025 | businesswire.com

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

May 1, 2025 | finance.yahoo.com

PureTech to Present Results from Phase 2b ELEVATE…

May 1, 2025 | pharmiweb.comP

PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript

April 30, 2025 | seekingalpha.com

PureTech Announces Annual Results for Year Ended December 31, 2024

April 30, 2025 | businesswire.com

PureTech Health Stock Price, Quotes and Forecasts | NASDAQ:PRTC | Benzinga

April 22, 2025 | benzinga.com

Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

April 10, 2025 | markets.businessinsider.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

PureTech Health Shares Fall After Nordic Capital Withdraws Offer Plan

April 8, 2025 | marketwatch.com

Nordic Capital steps away from potential PureTech Health buyout

April 7, 2025 | fiercebiotech.comF

PureTech Health plc Statement Regarding Press Speculation

April 7, 2025 | businesswire.com

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

March 11, 2025 | finance.yahoo.com

PureTech to Present at the Leerink Partners Global Healthcare Conference

February 25, 2025 | finance.yahoo.com

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via ...

February 12, 2025 | businesswire.com

Trend Tracker for (PRTC)

February 2, 2025 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC, HRMY, BEAM, and GLPG Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.80 -0.34 (-1.98%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$17.16 +0.36 (+2.17%)

As of 04:41 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Galapagos NASDAQ:GLPG

$27.98 -0.09 (-0.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$28.02 +0.04 (+0.13%)

As of 04:00 AM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Harmony Biosciences NASDAQ:HRMY

$31.98 +0.12 (+0.38%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$32.15 +0.17 (+0.52%)

As of 04:05 AM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

PureTech Health NASDAQ:PRTC

$17.15 -0.79 (-4.40%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$17.97 +0.82 (+4.78%)

As of 04:00 AM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time